Download

Full Text

• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150.
• Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in acute and chronic kidney disease. N Engl J Med 2022;386:2120–8. https://doi.org/10.1056/NEJMra2201153
• van Mil D, Kieneker LM, Evers-Roeten B et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. The Lancet 2023;402:1052–64. http://doi.org/10.1016/S0140-6736(23)00876-0
• Manns B, Hemmelgarn B, Tonelli M et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869. http://www.bmj.com/content/341/bmj.c5869.abstract.
• Yeo SC, Wang H, Ang YG et al. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review. Clinical Kidney Journal 2024;17:sfad137. https://doi.org/10.1093/ckj/sfad137
• Delanaye P, Wissing KM, Scheen AJ. Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. Clinical Kidney Journal 2021;14:2463–71. https://doi.org/10.1093/ckj/sfab096
• Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–46. https://doi.org/10.1056/ NEJMoa2024816
• Bakris GL, Agarwal R, Anker SD et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–29. https://doi.org/10.1056/ NEJMoa2025845
• The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388: 117–27. https://doi.org/10.1056/NEJMoa2204233